Alteration of tobacco alkaloid content through modification of specific cytochrome P450 genes

US9228194B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9228194-B2
Application numberUS-201213361159-A
CountryUS
Kind codeB2
Filing dateJan 30, 2012
Priority dateNov 12, 2007
Publication dateJan 5, 2016
Grant dateJan 5, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Compositions and methods for reducing the level of nornicotine and N′-nitrosonornicotine (NNN) in Nicotiana plants and plant parts thereof are provided. The compositions comprise isolated polynucleotides and polypeptides for cytochrome P450s that are involved in the metabolic conversion of nicotine to nornicotine in these plants. Expression cassettes, vectors, plants, and plant parts thereof comprising inhibitory sequences that target expression or function of the disclosed cytochrome P450 polypeptides are also provided. Methods for the use of these novel sequences to inhibit expression or function of cytochrome P450 polypeptides involved in this metabolic conversion are also provided. The methods find use in the production of tobacco products that have reduced levels of nornicotine and its carcinogenic metabolite, NNN, and thus reduced carcinogenic potential for individuals consuming these tobacco products or exposed to secondary smoke derived from these products.

First claim

Opening claim text (preview).

What is claimed is: 1. A tobacco product comprising cured tobacco material made from a tobacco plant comprising a first mutation within the coding region of a wild type allele encoding a nicotine demethylase having the amino acid sequence of SEQ ID NO: 2, wherein said first mutation reduces the activity of said nicotine demethylase. 2. The tobacco product according to claim 1 , wherein said tobacco plant further comprises a second mutation within the coding region of a wild type allele encoding a nicotine demethylase having the amino acid sequence of SEQ ID NO:13, wherein said second mutation reduces the activity of said nicotine demethylase. 3. The tobacco product according to claim 1 , wherein said tobacco material is made by a curing process selected from the group consisting of flue curing, air curing, and fire curing. 4. The tobacco product according to claim 1 , wherein said tobacco product is selected from the group consisting of a cigar, a cigarette, pipe tobacco, a cigarillo, a non-ventilated or vented recess filter cigarette, a dissolving strip, a gum, a tablet, snuff, and chewing tobacco. 5. The tobacco product according to claim 1 , wherein said cured tobacco material comprises a lower level of nornicotine or N′-nitrosonornicotine compared to cured tobacco material made from a tobacco plant comprising said wild type allele. 6. The tobacco product according to claim 1 , wherein the conversion of nicotine to nornicotine in said cured tobacco material is selected from the group consisting of less than 0.3%, less than 0.5%, less than 0.7%, between 0.1%-0.5%, between 0.1%-0.4%, between 0.1%-0.7%, and between 0.1%-1.0%. 7. The tobacco product according to claim 1 , wherein said tobacco plant has a non-converter phenotype and reduced nicotine demethylase activity from said first locus. 8. The tobacco product according to claim 1 , wherein said tobacco plant is a hybrid. 9. The tobacco product according to claim 1 , wherein said tobacco plant is selected from the group consisting of a Burley type, a dark type, a flue-cured type, and an Oriental type. 10. The tobacco product according to claim 1 , wherein said first mutation results in a substitution at an amino acid residue in a position selected from the group consisting of residues 235, 449, 174, 410, 224, 72, 143, and 422, wherein said amino acid position numbering is according to SEQ ID NO:2. 11. The tobacco product according to claim 1 , wherein said first mutation results in a Tryptophan to stop codon substitution at amino acid position 422, wherein said amino acid position numbering is according to SEQ ID NO:2. 12. The tobacco product according to claim 2 , wherein said first or second mutation is selected from the group consisting of a point mutation, a deletion, an insertion, and an inversion. 13. The tobacco product according to claim 2 , wherein said second mutation results in a Tryptophan to stop codon substitution at amino acid position 329, wherein said amino acid position numbering is according to SEQ ID NO:13. 14. The tobacco product according to claim 2 , wherein said tobacco plant is homozygous for said first or second mutation, or both. 15. Cured tobacco material made from a tobacco plant comprising a first mutation within the coding region of a wild type allele encoding a nicotine demethylase having the amino acid sequence of SEQ ID NO:2, wherein said first mutation reduces the activity of said nicotine demethylase. 16. The cured tobacco material according to claim 15 , wherein said tobacco plant further comprises a second mutation within the coding region of a wild type allele encoding a nicotine demethylase having the amino acid sequence of SEQ ID NO: 13, wherein said second mutation reduces the activity of said nicotine demethylase. 17. The tobacco product according to claim 11 , wherein said second mutation results in a Tryptophan to stop codon substitution at amino acid position 329, wherein said amino acid position numbering is according to SEQ ID NO:13.

Assignees

Inventors

Classifications

  • involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine · CPC title

  • Processes for producing mutations, e.g. treatment with chemicals or with radiation (specific mutations prepared by genetic engineering on plant cell or plant tissues C12N15/00 {; process for producing transgenic plants C12N15/82}) · CPC title

  • C12N9/0073Primary

    with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13 · CPC title

  • Leaves · CPC title

  • Nicotiana, e.g. tobacco · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9228194B2 cover?
Compositions and methods for reducing the level of nornicotine and N′-nitrosonornicotine (NNN) in Nicotiana plants and plant parts thereof are provided. The compositions comprise isolated polynucleotides and polypeptides for cytochrome P450s that are involved in the metabolic conversion of nicotine to nornicotine in these plants. Expression cassettes, vectors, plants, and plant parts thereof …
Who is the assignee on this patent?
Dewey Ralph E, Siminszky Balazs, Bowen Steven W, and 3 more
What technology area does this patent fall under?
Primary CPC classification C12N15/8243. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jan 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).